Organisation paid for research Program year 2025 Source: CMS Open Payments

US Oncology Res LLC

Neither a doctor nor a teaching hospital

Research payments

$33,509,183

1,605 payments

Through program year 2025, US Oncology Res LLC is reported as receiving $33,509,183 in research payments, across 1,605 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$2,773,051	119
2024	Research	$2,444,791	162
2023	Research	$1,922,520	133
2022	Research	$3,426,542	187
2021	Research	$6,192,984	280
2020	Research	$8,338,333	393
2019	Research	$8,410,962	331

Breakdown

Who paid Research payments · program years 2019–2025

E.R. Squibb & Sons, L.L.C. $27,367,717 1,415 payments
Mirati Therapeutics, Inc. $3,774,813 147 payments
Celgene Corporation $2,366,654 43 payments

Studies the money was for Research payments · program years 2019–2025

Phase II III 1L CRC Nivo CT w pt segmentation rational combos $3,118,280 28 payments
Ph III MIBC Neoadjuvant 1L Bladder IDO Nivo chemo $2,117,325 39 payments
Phase IIB 1L NSCLC Flat Dose Nivo Combo Schedule Safety $1,571,082 50 payments
A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer $1,327,137 46 payments
Phase I II FIH Monotherapy Nivo Combination $1,305,472 33 payments
Phase I IIA FIH IL8 Nivo Combo Study $1,214,121 15 payments
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 $1,093,798 42 payments
Phase IIA 2L Prostate Ipi Nivo Combo $1,001,843 10 payments
A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation $950,538 16 payments
Phase III 1L Metastatic RCC Nivo Ipi Cabo $786,328 22 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.